CRISPR biotech Intellia cuts staff as it eyes 2027 launch
pharmaphorum
JANUARY 10, 2025
Eyeing a first commercial launch in 2027, Intellia is re-prioritising by cutting 27% of its workforce and shelving a lung disease candidate.
2027 Related Topics 
AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027: GlobalData
Express Pharma
APRIL 25, 2024
Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales of $4 billion by 2027, according to an analyst consensus forecast by GlobalData. Expected revenues in these indications will reach over 68 per cent of the global PARP inhibitors market by 2027.
Chemotherapy 
116
116 Chemotherapy 116
116 Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Opinion: Want to end historic health care strikes? Fix a broken, outdated reimbursement model
STAT
OCTOBER 26, 2023
About 800,000 nurses plan to leave the workforce by 2027, and more than half of newly graduated nurses are leaving the profession within two years. The Kaiser strike is over, for now, but there is no clear resolution in place, and other strikes are still under way or on the horizon.
333 
STAT+: Wegovy is among drugs set to be targeted in the next round of Medicare price negotiations, researchers say
STAT
SEPTEMBER 23, 2024
1, and the negotiated prices of those drugs take effect in 2027. Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs. Medicare will announce that list by Feb.
Teva is eyeing $2.5bn in Austedo sales in 2027
pharmaphorum
MAY 19, 2023
Teva is eyeing $2.5bn in Austedo sales in 2027 Phil.Taylor Fri, 05/19/2023 - 09:41 Bookmark this
98 
Tories pledge £250m each year for Pharmacy First 2027-2030
The Pharmacist
JUNE 11, 2024
The Conservative Party has set out spending plans of £250m each year on Pharmacy First from 2027 to 2030, as it pledges to expand the service to include more conditions like acne and chest infections.
HHMI’s move to diversify funding sparks debate about ‘biomedical elite’
STAT
DECEMBER 13, 2024
The nonprofit Howard Hughes Medical Institute (HHMI) will bar institutions that already have two or more beneficiaries of its Investigator Program from applying for a round of funds to be awarded in 2027.
267 
Oligonucleotide synthesis market to reach $16.7 billion by 2027
European Pharmaceutical Review
DECEMBER 9, 2022
billion by 2027 during the forecast period, due to the rise in ongoing clinical trials for oligonucleotide-based therapies in key therapeutic sectors such as oncology. billion by 2027 appeared first on European Pharmaceutical Review. The research projected a compound annual growth rate (CAGR) of 16.8 percent from $7.7 billion in 2022.
Compounding 98
98 Compounding 98
98 
Pharmaceutical sterility testing market to grow from $2.07b in 2027
European Pharmaceutical Review
FEBRUARY 1, 2023
billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29
Compounding 98
98 Compounding 98
98 
STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices
STAT
DECEMBER 7, 2023
One expires next year and the other in 2027, well beyond the original patent expiration date. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.
Drug Pricing 315
315 
STAT+: Key House panel proposes lowering out-of-pocket drug costs in Medicare
STAT
JULY 24, 2023
The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.
Packaging 246
246 
Opinion: STAT+: 4 concrete steps to realize the AI Bill of Rights for clinical decision support software
STAT
JANUARY 17, 2023
The number of health care-related artificial intelligence models on the market has increased steadily over the past decade, with the health care AI market expected to grow from $7 billion today to $67 billion in 2027.
254 
Pharmaceuticals & Medical Devices Bureau of India participates in 43rd Edition of IITF 2024
Express Pharma
NOVEMBER 25, 2024
The Government aims to expand the reach of PMBJP by increasing the number of Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) to 25,000 by March 2027. The post Pharmaceuticals & Medical Devices Bureau of India participates in 43rd Edition of IITF 2024 appeared first on Express Pharma.
104 
Akums Group enters into a partnership for European market expansion
Express Pharma
DECEMBER 26, 2024
The commercial supply of these products is expected to begin in 2027 and will continue to be supplied till 2032. Under this collaboration, Akums Group will produce and supply multiple SKUs of oral liquid formulations, which the partner company will market across various European countries.
105 
STAT+: Pharmalittle: We’re reading about Chinese drugmakers weighing sales, Medicare price talks, and more
STAT
OCTOBER 3, 2024
1, 2025, the Centers for Medicare and Medicaid Services will select the costliest prescription medications to negotiate on, with prices coming into effect in 2027.
253 
Fragile X syndrome market to quadruple to $111.9 million in US and Germany by 2030, forecasts GlobalData
Express Pharma
FEBRUARY 18, 2025
per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. The fragile X syndrome (FXS) market across the US and Germany is projected to experience explosive growth, quadrupling from $28.7 million in 2025 to $111.9 million by 2030, a CAGR of 31.3
Labelling 99
99 Labelling 99
99 
STAT+: Pharmalittle: We’re reading about Novo’s Wegovy approval in China, a Merck KGaA cancer trial failure, and more
STAT
JUNE 25, 2024
The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.
273 
The IRA will lower U.S. drug spending, CMS finds — but not for awhile
PharmaVoice
JULY 1, 2024
government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027. As the first 10 drugs undergo price negotiations with the U.S.
130 
CPE committee won’t change to include more non-CCA members until 2027
The Pharmacist
FEBRUARY 20, 2025
No changes will be introduced to the Community Pharmacy England (CPE) committee membership until the current term ends in 2027, notes from the negotiator's latest meeting have confirmed. But the two non-Company Chemists' Association (CCA) 10+ multiple observers will remain as such until March 2027.
STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs
STAT
NOVEMBER 20, 2023
Under the new agreement, the level of allowed growth in drug sales will increase from 2% in 2024 to 4% by 2027. The current plan, which has drawn the ire of pharma companies, requires drug companies to pay rebates back to the U.K. if spending on medicines increases by more than 2% a year. Continue to STAT+ to read the full story…
279 
Novavax reaches settlement with UK Health Security Agency over COVID-19 vaccine agreement
Express Pharma
NOVEMBER 5, 2024
million over a three-year period, ending on June 30, 2027, a filing showed. Under terms of the deal, the company and the UKHSA agreed to settle the outstanding amount under dispute related to upfront payments received by Novavax from the health agency. Novavax has agreed to refund $123.8 The first installment payment is due on Nov.
Vaccines 103
103 Vaccines 103
103 
Alkermes fends off generic versions of Vivitrol until 2027
Pharmaceutical Technology
AUGUST 31, 2023
Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.
52 
STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs
STAT
JULY 25, 2023
The House Ways & Means Committee proposed a package that includes a new provision to ensure Medicare patients pay for medicines they pick up at pharmacies based on discounted prices insurers negotiate with drugmakers, instead of higher list prices, starting in 2027 , STAT reports.
Packaging 246
246 
Gilead expands Arcellx cancer cell therapy deal
BioPharma Dive
NOVEMBER 15, 2023
The deal gives Gilead an estimated 13% ownership in Arcellx and extends the company’s cash runway into 2027.
117 
Zydus Chairman Pankaj Patel highlights people-centric leadership at SOUL launch
Express Pharma
FEBRUARY 23, 2025
The institution will offer a variety of leadership programmes, ranging from short workshops to extended courses lasting 9 to 12 months, starting in March 2027. SOULs mission is to empower young individuals for roles in public sectors such as health, education, rural development, and sanitation.
Communication 101
101 Communication 101
101 
Roquette unveils refreshed coatings platform for pharma and nutra markets
Express Pharma
FEBRUARY 11, 2025
billion by 2027, driven by increasing demand for innovative patient-friendly dosage forms, said Paul Smaltz, Head of the Pharmaceutical Solutions Business Unit at Roquette. The platform provides manufacturers with ready-to-use coating premixes for pharmaceutical prescription, nutraceutical, and over-the-counter (OTC) products.
Dosage 85
85 Dosage 85
85 
BMS extends its cost-cutting drive by another $2bn
pharmaphorum
FEBRUARY 6, 2025
BMS is extending its bid to cut costs by $1.5bn before the end of this year, backed by 2,200 job cuts, adding a target of another $2bn by end-2027.
93 Novo Financially Commits $220 Million Toward New Plant in Denmark
Pharmaceutical Commerce
AUGUST 19, 2024
The 86,000 square-foot Køge facility will be fully functional by 2027.
81 
Vyvgart Hytrulo gains first APAC approval in China, redefining CIDP care: GlobalData
Express Pharma
NOVEMBER 21, 2024
per cent from 56,009 in 2023 to 56,163 in 2027. According to GlobalData’s Pharmaceutical Intelligence Center, the diagnosed prevalent cases of CIDP in China are expected to increase at an annual growth rate (AGR) of 0.2
Immunity 96
96 
NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027
Putting Patients First Blog
JULY 2, 2024
Clarification on QALY Metrics The NHC appreciates CMS’ commitment to excluding Quality-Adjusted Life Years (QALYs) from the negotiation process as outlined in the 2027 draft guidance. Valuing life differently based on disability status, age, or other special populations is inappropriate.
Drug Pricing 52
52 
Biologics to overtake small molecules in solid tumors treatment by 2027
Outsourcing Pharma
OCTOBER 24, 2023
Traditionally, the pharmaceutical landscape has been dominated by small molecules.
64 
South Africa launches ‘unprecedented’ investigation of Johnson & Johnson over TB drug prices
The Guardian - Pharmaceutical Industry
SEPTEMBER 21, 2023
The commission’s investigation was made public last week by the health department and the Health Justice Initiative (HJI) legal organisation at a media briefing of Médecins Sans Frontières (MSF).
Drug Pricing 108
108 Drug Pricing 108
108 
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
BioPharma Dive
FEBRUARY 6, 2025
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference call.
CPHI Report: Biologics, Tides Approvals Will Surpass Small Molecules by 2027
PharmaTech
SEPTEMBER 12, 2024
Seventeen biologics and nine tides—five peptides and four oligonucleotides—were approved in 2023 alone, with further growth predicted.
52 
JP Nadda inaugurates Jan Aushadhi Diwas celebrations
Express Pharma
MARCH 2, 2025
Under PMBJP, the government has set a target to open 25000 JAKs by March 31, 2027 across the country. The product basket of PMBJP comprises 2047 drugs and 300 surgical equipment which are sold at retail shops at 50 per cent to 80 per cent cheaper than branded medicines.
Report: Pharma Automation Market to Reach $8.2B by 2027
Pharmaceutical Commerce
APRIL 5, 2023
Rise in value attributed to the ongoing decentralization of pharmacies.
52 
Report Identifies 15 Key Drugs Predicted to Achieve Blockbuster Status by 2027
Pharmacy Times
JANUARY 10, 2023
The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.
52 
NHC Comments on Negotiation Data Elements and Drug Price Negotiation Process for Initial Price Applicability Year 2027 under Sections 11001 and 11002 of the IRA ICR Forms
Putting Patients First Blog
SEPTEMBER 3, 2024
We strongly urge CMS to address these issues in the IPAY 2027 portal to ensure that all participants, regardless of their familiarity with technology or survey formats, can contribute their insights without unnecessary difficulty. Conclusion The NHC appreciates the opportunity to provide input on the IRA 2027 Drug Price Negotiation ICR.
Drug Pricing 52
52 
CPHI Barcelona: CMOs Expected to Account for 45% Available Bio Capacity in 2027
PharmaTech
OCTOBER 26, 2023
As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.
52 
UK £62 billion behind in R&D global investment share, report reveals
European Pharmaceutical Review
NOVEMBER 2, 2022
Somewhat ambitious: Meet three percent of GDP by 2027, building on aspirations set out by the Confederation of British Industry (CBI), the European Commission (EC) and opposition political parties. The government would need to invest an extra £1 billion in R&D by 2027. Private investment would also need to rise by £0.8
Biologics emerge as dominating molecule type in solid tumour indication
Pharmaceutical Technology
OCTOBER 6, 2023
Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.
59 
AstraZeneca investment to increase biologic capacity in Sweden
European Pharmaceutical Review
AUGUST 27, 2024
Manufacturing of the biologic products in the expanded Sweden Biomanufacturing Center is planned to begin from Q4 of 2027, according to AstraZeneca. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden”, Alfredsson continued.
115 
MD Logistics Welcomes Electric Vehicles to North Carolina Fleet
Pharmaceutical Commerce
AUGUST 30, 2024
The 3PL plans to convert all its trucks to electric by 2027.
52 
Global Medicines Market to Grow 3-6% Annually to $1.9 Trillion through 2027, Says IQVIA
Pharmaceutical Commerce
JANUARY 25, 2023
Annual report finds continuing impact of COVID-19 on global markets
52 
Let's personalize your content